|
End-of-day quote
Shanghai S.E.
2026-09-11
|
5-day change | 1st Jan Change | ||
| 66.34 CNY | -2.27% |
|
-5.36% | -2.54% |
| 09-09 | Gan&Lee Pharmaceuticals Co., Ltd. Doses First Participant In First-In-Human Phase 1 Study Of GZC8072 Tablets | CI |
| 09-08 | Gan & Lee Pharmaceuticals Doses First Subject in Weight Loss Drug Trial | MT |
| Market Cap | 39.49B 5.89B 5.07B 4.8B 4.35B 8.17B 562B 8.21B 57.03B 21.93B 286B 22.1B 21.62B 904B | P/E 2026 * |
27.6x | P/E 2027 * | 24.3x |
|---|---|---|---|---|---|
| Enterprise Value | 36.28B 5.41B 4.66B 4.41B 4B 7.5B 517B 7.54B 52.4B 20.15B 263B 20.31B 19.87B 831B | EV / Sales 2026 * |
7.09x | EV / Sales 2027 * | 6.12x |
| Free-Float |
57.83% | Yield 2026 * |
0.36% | Yield 2027 * | 0.41% |
| 1 day | -2.27% | ||
| 1 week | -5.36% | ||
| Current month | -3.76% | ||
| 1 month | -14.38% | ||
| 3 months | +19.27% | ||
| 6 months | +6.78% | ||
| Current year | -2.54% |
| 1 week | 65.53 |  | 69.9 |
| 1 month | 65 | | 74.97 |
| Current year | 51.51 | | 79.99 |
| 1 year | 51.51 | | 82.25 |
| 3 years | 32.1 | | 82.25 |
| 5 years | 30.53 | | 83.38 |
| 10 years | 30.53 | | 204.41 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Chen
CEO | Chief Executive Officer | 46 | 2025-05-29 |
Qi Wang
DFI | Director of Finance/CFO | 44 | 2026-03-08 |
Ting Jia
CTO | Chief Tech/Sci/R&D Officer | - | 2026-03-08 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhong Ru Gan
CHM | Chairman | 78 | 1998-06-16 |
Kai Du
BRD | Director/Board Member | 49 | 2009-12-31 |
Wei Qiang Song
BRD | Director/Board Member | 44 | 2015-09-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/3/26 | Sell | Director | -10,000 | 0.0019% | ||
| 9/3/26 | Sell | Executive/Senior Manager | -3,000 | 0.0006% | ||
| 9/2/26 | Sell | Executive/Senior Manager | -1,000 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.27% | -5.36% | -10.53% | +54.42% | 5.89B | |
| -1.48% | -5.59% | +39.55% | -5.42% | 78.04B | |
| +5.38% | -1.09% | +512.38% | +32.58% | 57.48B | |
| +2.68% | -0.93% | -16.09% | -35.72% | 57.4B | |
| -0.56% | -2.21% | -11.34% | +27.29% | 48.81B | |
| +0.61% | -1.64% | +0.66% | +150.91% | 45.5B | |
| +0.80% | -1.67% | +49.90% | -15.15% | 32.08B | |
| -1.47% | -4.17% | +46.17% | +92.50% | 24.62B | |
| +3.53% | -4.39% | +1.31% | +156.56% | 20.77B | |
| +1.28% | -1.02% | +63.15% | +98.84% | 15.75B | |
| Average | +0.86% | -3.89% | +67.52% | +55.68% | 38.63B | |
| Weighted average by Cap. | +1.09% | -3.72% | +90.05% | +37.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 5.11B 762M 657M 622M 564M 1.06B 72.83B 1.06B 7.39B 2.84B 37.05B 2.86B 2.8B 117B | 5.75B 858M 739M 700M 634M 1.19B 81.95B 1.2B 8.31B 3.2B 41.69B 3.22B 3.15B 132B |
| Net income | 1.44B 214M 185M 175M 159M 297M 20.48B 299M 2.08B 799M 10.42B 805M 788M 32.93B | 1.64B 244M 210M 199M 180M 338M 23.29B 340M 2.36B 908M 11.85B 916M 896M 37.45B |
| Net Debt | -3.2B -477M -411M -389M -353M -662M -45.61B -666M -4.63B -1.78B -23.2B -1.79B -1.75B -73.32B | -4.28B -638M -549M -520M -471M -884M -60.91B -889M -6.18B -2.38B -30.99B -2.39B -2.34B -97.92B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | CN¥66.34 | -2.27% | 5,645,487 |
| 26-09-10 | CN¥67.88 | -1.49% | 3,603,432 |
| 26-09-09 | CN¥68.91 | -0.69% | 3,651,181 |
| 26-09-08 | CN¥69.39 | +0.39% | 4,515,932 |
| 26-09-07 | CN¥69.12 | -1.40% | 4,668,004 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 603087 Stock
Select your edition
All financial news and data tailored to specific country editions
